Prospects in the management of patients with follicular lymphoma beyond first-line therapy
The management of patients with relapsed or refractory follicular lymphoma has evolved markedly in the last decade, with the availability of new classes of agents (phosphoinositide 3-kinase inhibitors, immunomodulators, epigenetic therapies, and chimeric antigen receptor T cells) supplementing the...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ferrata Storti Foundation
2022-01-01
|
| Series: | Haematologica |
| Online Access: | https://haematologica.org/article/view/10487 |